US2013123481A1PendingUtilityA1

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

64
Assignee: modeRNA TherapeuticsPriority: Oct 3, 2011Filed: Jan 17, 2013Published: May 16, 2013
Est. expiryOct 3, 2031(~5.2 yrs left)· nominal 20-yr term from priority
Inventors:Antonin De FougerollesAtanu RoyStephane BancelPaul Hatala
C12N 15/11A61P 37/04A61K 48/0066C12N 15/67A61P 43/00C07K 14/535C07H 21/02A61K 38/193A61K 9/0019A61K 48/0033A61K 9/0021A61K 48/0075A61K 9/5123
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated mRNA encoding a polypeptide of interest, said isolated mRNA comprising at least a first and a second modified nucleoside; wherein said first modified nucleoside is N1-methylpseudouridine and said second modified nucleoside is neither pseudouridine or 5-methylcytosine. 
     
     
         2 . The isolated mRNA of  claim 1 , wherein a second modified nucleoside is selected from the group consisting of a modified purine nucleoside and a modified pyrimidine nucleoside. 
     
     
         3 . The isolated mRNA of  claim 2 , wherein the second modified nucleoside is a modified purine nucleoside and the modified purine nucleoside is selected from the group consisting of adenosine and guanosine. 
     
     
         4 . The isolated mRNA of  claim 3 , wherein the modified purine nucleoside comprises at least one modification selected from the group consisting of a base modification and a sugar modification. 
     
     
         5 . The isolated mRNA of  claim 4 , wherein the at least one modification is on the sugar. 
     
     
         6 . The isolated mRNA of  claim 2 , wherein the modified pyrimidine nucleoside is selected from the group consisting of cytidine and uridine. 
     
     
         7 . The isolated mRNA of  claim 6 , wherein the modified pyrimidine nucleoside comprises at least one modification selected from the group consisting of a base modification and a sugar modification. 
     
     
         8 . The isolated mRNA of  claim 7 , wherein the at least one modification is on the sugar. 
     
     
         9 . The isolated mRNA of  claim 2  further comprising a third modified nucleoside. 
     
     
         10 . The isolated mRNA of  claim 9 , wherein the third modified nucleoside is selected from the group consisting of a modified purine nucleoside and a modified pyrimidine nucleoside. 
     
     
         11 . The isolated mRNA of  claim 10 , wherein the third modified nucleoside is purine and the modified purine nucleoside comprises at least one modification selected from the group consisting of a base modification and a sugar modification. 
     
     
         12 . The isolated mRNA of  claim 11 , wherein the at least one modification is on the sugar. 
     
     
         13 . The isolated mRNA of  claim 10 , wherein the third modified nucleoside is pyrimidine and the modified pyrimidine nucleoside comprises at least one modification selected from the group consisting of a base modification and a sugar modification. 
     
     
         14 . The isolated mRNA of  claim 13 , wherein the at least one modification is on the sugar.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.